Faisal T, Hussain T
FASEB Bioadv. 2025; 7(3):e1486.
PMID: 40060944
PMC: 11886600.
DOI: 10.1096/fba.2024-00180.
Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A
Mol Cancer. 2025; 24(1):58.
PMID: 40011944
PMC: 11863469.
DOI: 10.1186/s12943-025-02267-0.
Zhou Y, Tang J, Weng M, Zhang H, Lai M
Adv Sci (Weinh). 2024; 12(6):e2413953.
PMID: 39679842
PMC: 11809390.
DOI: 10.1002/advs.202413953.
Periferakis A, Tsigas G, Periferakis A, Tone C, Hemes D, Periferakis K
Curr Issues Mol Biol. 2024; 46(9):9721-9759.
PMID: 39329930
PMC: 11430067.
DOI: 10.3390/cimb46090578.
Tsuboi D, Nagai T, Yoshimoto J, Kaibuchi K
Front Mol Neurosci. 2024; 17:1376762.
PMID: 38516040
PMC: 10954900.
DOI: 10.3389/fnmol.2024.1376762.
Current and Emerging Pharmacological Therapies for Cushing's Disease.
Divaris E, Kostopoulos G, Efstathiadou Z
Curr Pharm Des. 2024; 30(10):757-777.
PMID: 38424426
DOI: 10.2174/0113816128290025240216110928.
Somatostatin and Somatostatin Receptors in Tumour Biology.
Kumar U
Int J Mol Sci. 2024; 25(1).
PMID: 38203605
PMC: 10779198.
DOI: 10.3390/ijms25010436.
Long-term efficacy and safety of subcutaneous pasireotide alone or in combination with cabergoline in Cushing's disease.
Feelders R, Fleseriu M, Kadioglu P, Bex M, Gonzalez-Devia D, Boguszewski C
Front Endocrinol (Lausanne). 2023; 14:1165681.
PMID: 37876540
PMC: 10593462.
DOI: 10.3389/fendo.2023.1165681.
Pituitary Tumorigenesis-Implications for Management.
Vamvoukaki R, Chrysoulaki M, Betsi G, Xekouki P
Medicina (Kaunas). 2023; 59(4).
PMID: 37109772
PMC: 10145673.
DOI: 10.3390/medicina59040812.
Functional Heterodimerization between the G Protein-Coupled Receptor GPR17 and the Chemokine Receptors 2 and 4: New Evidence.
Daniele S, Saporiti S, Capaldi S, Pietrobono D, Russo L, Guerrini U
Int J Mol Sci. 2023; 24(1).
PMID: 36613703
PMC: 9820414.
DOI: 10.3390/ijms24010261.
Transcriptomic Profiles of Normal Pituitary Cells and Pituitary Neuroendocrine Tumor Cells.
Oh J, Osorio R, Jung J, Carrete L, Choudhary N, Lad M
Cancers (Basel). 2023; 15(1).
PMID: 36612109
PMC: 9817686.
DOI: 10.3390/cancers15010110.
Dopamine-inhibited POMCDrd2+ neurons in the ARC acutely regulate feeding and body temperature.
Gaziano I, Corneliussen S, Biglari N, Neuhaus R, Shen L, Sotelo-Hitschfeld T
JCI Insight. 2022; 7(21).
PMID: 36345942
PMC: 9675440.
DOI: 10.1172/jci.insight.162753.
Dimerization of GPCRs: Novel insight into the role of FLNA and SSAs regulating SST and SST homo- and hetero-dimer formation.
Treppiedi D, Marra G, Di Muro G, Catalano R, Mangili F, Esposito E
Front Endocrinol (Lausanne). 2022; 13:892668.
PMID: 35992099
PMC: 9389162.
DOI: 10.3389/fendo.2022.892668.
Efficacy of cabergoline add-on therapy in patients with acromegaly resistance to somatostatin analogs treatment and the review of literature.
Kizilgul M, Duger H, Nasiroglu N, Sencar E, Hepsen S, Akhanli P
Arch Endocrinol Metab. 2022; 66(3):278-285.
PMID: 35612842
PMC: 9832853.
DOI: 10.20945/2359-3997000000481.
Class A and C GPCR Dimers in Neurodegenerative Diseases.
Caniceiro A, Bueschbell B, Schiedel A, Moreira I
Curr Neuropharmacol. 2022; 20(11):2081-2141.
PMID: 35339177
PMC: 9886835.
DOI: 10.2174/1570159X20666220327221830.
Disruption of 5-hydroxytryptamine 1A receptor and orexin receptor 1 heterodimer formation affects novel G protein-dependent signaling pathways and has antidepressant effects in vivo.
Zhang R, Li D, Mao H, Wei X, Xu M, Zhang S
Transl Psychiatry. 2022; 12(1):122.
PMID: 35338110
PMC: 8956632.
DOI: 10.1038/s41398-022-01886-1.
Current and Emerging Medical Therapies in Pituitary Tumors.
Sahakian N, Castinetti F, Brue T, Cuny T
J Clin Med. 2022; 11(4).
PMID: 35207228
PMC: 8877616.
DOI: 10.3390/jcm11040955.
GPCR systems pharmacology: a different perspective on the development of biased therapeutics.
Eiger D, Pham U, Gardner J, Hicks C, Rajagopal S
Am J Physiol Cell Physiol. 2022; 322(5):C887-C895.
PMID: 35196164
PMC: 9037395.
DOI: 10.1152/ajpcell.00449.2021.
Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.
Pivonello C, Patalano R, Negri M, Pirchio R, Colao A, Pivonello R
Front Endocrinol (Lausanne). 2022; 12:791633.
PMID: 35095761
PMC: 8789681.
DOI: 10.3389/fendo.2021.791633.
Disrupting GPCR Complexes with Smart Drug-like Peptides.
Gallo M, Defaus S, Andreu D
Pharmaceutics. 2022; 14(1).
PMID: 35057055
PMC: 8779866.
DOI: 10.3390/pharmaceutics14010161.